Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192,674 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Kadia TM, et al. Among authors: wang x. J Clin Oncol. 2022 Nov 20;40(33):3848-3857. doi: 10.1200/JCO.21.02823. Epub 2022 Jun 15. J Clin Oncol. 2022. PMID: 35704787 Free PMC article. Clinical Trial.
Extraosseous osteosarcoma: response to treatment and long-term outcome.
Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW, Wang X, Feig BW, Hunt KK, Lin PP, Weber KL, Chen LL, Zagars GK, Pollock RE, Benjamin RS, Pisters PW. Ahmad SA, et al. Among authors: wang x. J Clin Oncol. 2002 Jan 15;20(2):521-7. doi: 10.1200/JCO.2002.20.2.521. J Clin Oncol. 2002. PMID: 11786582
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Estey EH, et al. Blood. 2002 Jun 15;99(12):4343-9. doi: 10.1182/blood.v99.12.4343. Blood. 2002. PMID: 12036860 Free article. Clinical Trial.
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. Wierda W, et al. Among authors: wang x. Cancer. 2006 Jan 15;106(2):337-45. doi: 10.1002/cncr.21554. Cancer. 2006. PMID: 16353201 Free article.
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Wierda WG, et al. Among authors: wang x. Blood. 2007 Jun 1;109(11):4679-85. doi: 10.1182/blood-2005-12-051458. Epub 2007 Feb 13. Blood. 2007. PMID: 17299097 Free article.
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Borthakur G, Kantarjian H, Wang X, Plunkett WK Jr, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Borthakur G, et al. Among authors: wang x. Cancer. 2008 Dec 1;113(11):3181-5. doi: 10.1002/cncr.23927. Cancer. 2008. PMID: 18932257 Free PMC article. Clinical Trial.
192,674 results
You have reached the last available page of results. Please see the User Guide for more information.